ReviewFrontiers in immunology2019
Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
Open access · goldAbstract readCase ReportsReview
In one paragraph
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Clinicopathological features and outcomes of glomerular microangiopathy: a retrospective cohort study.Renal failure · 2026Article
- Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.Renal failure · 2026Review
- Kidney involvement in idiopathic multicentric Castleman disease-TAFRO syndrome: clinical spectrum, pathology and outcomes.Clinical kidney journal · 2026Article
- Clinical feature analysis of pediatric Castleman disease with renal involvement.Pediatric nephrology (Berlin, Germany) · 2026Article
- Morphological characteristics of the renal lesion in TAFRO syndrome and POEMS syndrome: a retrospective and multicenter study.Clinical and experimental nephrology · 2026Article
- A young woman with membranoproliferative glomerulonephritis and persistent hypocomplementemia: a case report.BMC nephrology · 2026Article
- Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.Biomedicines · 2024Review
- A case of TAFRO syndrome after vaccination, successfully treated with cyclosporine.BMC nephrology · 2024Article
- Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.Pathology oncology research : POR · 2024Article
- The experience of diagnosis and treatment for TAFRO syndrome.Annals of hematology · 2023Article
- Idiopathic multicentric castleman's disease mimicking immunoglobulin G4-related disease responding well to Bortezomib: a case report.BMC nephrology · 2023Article
- Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2023Review
- Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature.Journal of nephrology · 2023Review
- Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.Rheumatology (Oxford, England) · 2023Review
- Case Report: A case of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls.Frontiers in immunology · 2023Article
- To and TAFRO - a cryptic cause of acute renal failure: a case report.BMC nephrology · 2022Article
- TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.International journal of molecular sciences · 2021Review
- Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.BMC nephrology · 2021Review
- Borderline Case of TAFRO Syndrome and POEMS Syndrome.Internal medicine (Tokyo, Japan) · 2021Article
- Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.CEN case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Amélie LeursDépartement de Médecine Interne et Immunologie Clinique, CHU Lille, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), LIRIC INSERM U995, Université de Lille, Lille, France.
Viviane GnemmiDépartement d'Anatomo-Cyto-Pathologie, CHU Lille, Centre de Biologie Pathologie, Université de Lille, Lille, France.
Arnaud LionetDépartement de Néphrologie, CHU Lille, Université de Lille, Lille, France.
Loïc RenaudCHU Lille, Institut d'Immunologie, Université de Lille, Lille, France.
Jean-Baptiste GibierDépartement d'Anatomo-Cyto-Pathologie, CHU Lille, Centre de Biologie Pathologie, Université de Lille, Lille, France.
Marie-Christine CopinDépartement d'Anatomo-Cyto-Pathologie, CHU Lille, Centre de Biologie Pathologie, Université de Lille, Lille, France.
Eric HachullaDépartement de Médecine Interne et Immunologie Clinique, CHU Lille, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), LIRIC INSERM U995, Université de Lille, Lille, France.
Pierre-Yves HatronDépartement de Médecine Interne et Immunologie Clinique, CHU Lille, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), LIRIC INSERM U995, Université de Lille, Lille, France.
David LaunayDépartement de Médecine Interne et Immunologie Clinique, CHU Lille, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), LIRIC INSERM U995, Université de Lille, Lille, France.
David FajgenbaumDepartment of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, United States.
Louis TerriouDépartement de Médecine Interne et Immunologie Clinique, CHU Lille, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), LIRIC INSERM U995, Université de Lille, Lille, France.
Université de Lille · FRUniversité Lille Nord de France · FRCentre Hospitalier Universitaire de Lille · FRInserm · FRInstitut de Biologie de Lille · FRLille Inflammation Research International Center · FRUniversity of Pennsylvania · US
Funding
mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1MNHLBI NIH HHS R01 HL141408
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultCastleman DiseaseFemaleGlomerulonephritis, MembranoproliferativeHumansKidneyThrombotic Microangiopathiesidiopathic multicentric Castleman diseaseinterleukin-6membranoproliferative glomerulonephritisTAFRO syndromethrombotic microangiopathy glomerulopathyVEGF
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.